Clinical research in Europe is evolving quickly. What are the biggest challenges sponsors are facing today?
Many companies are not only racing against time. They are trying to reduce risk and uncertainty earlier.
That is especially visible in biotech and pharma companies with promising science. Investors, regulators and internal teams want stronger signals earlier. Does the product work? Is the risk acceptable? Is the next investment justified?
For us as a clinical research organization, the key challenge is no longer just running clinical studies efficiently. It is helping companies generate evidence that supports better decisions earlier in development, before larger investments are made. Sometimes, that evidence supports progression. Sometimes, it helps sponsors recognize early that a different path should be pursued. Both outcomes create value.
That means helping sponsors identify the most efficient path to generate the evidence needed for the next development decision and reduce uncertainty at key milestones.
For example, earlier evidence can come from designing early-phase studies around the decision sponsors need to make next. This may involve selecting the right volunteer population, endpoints or proof-of-concept approach to generate meaningful data as early as possible. That may include clinical pharmacology studies to support safety, PK/PD and dose decisions, human challenge trials to generate controlled proof-of-concept data in infectious disease, ADME to understand human drug behavior earlier or biomarker-led approaches to reduce uncertainty before larger studies begin. Or hybrid trial designs that include both healthy volunteers and patients, to connect early safety and pharmacology data with first patient insights in one development step.
We also see technology changing how clinical research is delivered. But AI, automation and data tools only create value when they are validated, controlled and used with human oversight.
How to turn regulatory compliance and clinical evidence generation into a strategic advantage?
We help companies think about evidence before execution starts. Compliance is often seen as something that slows development down. We see it differently. When regulatory thinking, clinical design, data strategy and documentation are aligned early, compliance becomes a way to create focus.
What claim do you need to support? Which endpoint really matters? Which data will influence the next decision? Where could the study become too complex, too slow or too weak to convince regulators, investors, partners or internal decision-makers?
By addressing these questions early, sponsors can focus resources on generating the evidence that matters most and avoid unnecessary complexity later in development.
This is also where Belgium offers a strong advantage for early clinical development in Europe. The country has competitive regulatory timelines for early-phase studies, including accelerated pathways for Phase I/II and monocentric Phase II trials. For sponsors, that can make Belgium an attractive route when they need reliable early evidence without losing time. For companies working toward critical development milestones, reducing start-up timelines can have a meaningful impact on overall development strategy and decision-making.
SGS is well positioned in that context, with deep early-phase expertise in Belgium. We support sponsors from Phase I to IV, helping them generate meaningful evidence efficiently through strengths in formulation, early clinical development, human challenge studies, ADME, clinical project management and monitoring, biometrics, as well as medical safety, regulatory and clinical trial laboratory testing.
Our focus is not to add layers. It is to help sponsors build a clearer, stronger development path. We act as an extension of the sponsor’s team.
That is the strategic value: better decisions and no avoidable surprises.
How can SGS’ presence in Medicon Valley support life science innovation and clinical development in the Nordics?
Medicon Valley has a strong ecosystem and a real culture of collaboration. That is exactly where a partner like SGS can add value. Innovation doesn’t move forward in isolation. A promising idea still needs the right development path: formulation, clinical strategy, regulatory thinking, evidence generation, data quality and operational execution.
For Nordic life science companies, this means easier access to expertise that helps answer practical questions early. What is the right formulation route? Which first-in-human or proof-of-concept strategy makes sense? What evidence will investors, partners, or regulators expect? Which study design can reduce uncertainty without adding unnecessary complexity?
SGS is connecting strong Nordic innovation with the scientific, regulatory and clinical development expertise needed to translate promising science into meaningful evidence, while providing the close collaboration and tailored guidance required to navigate complex development decisions.